Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- 12 Jul 2017 Planned End Date changed from 1 Dec 2020 to 15 Dec 2020.
- 12 Jul 2017 Planned primary completion date changed from 1 Dec 2020 to 15 Dec 2020.
- 06 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.